Regeneron and Sanofi to look into side effects of cholesterol drug candidate

|About: Regeneron Pharmaceutic... (REGN)|By:, SA News Editor

The FDA requests that Regeneron (REGN) and Sanofi (SNY) assess potential neurocognitive side effects of their late stage cholesterol drug alirocumab, a PCSK9 inhibitor.

Memory loss, impaired concentration and paranoia, though rare, have been associated with the use of statins for lowering LDL cholesterol.

Both firms disclosed in their regulatory filings that the appearance of these side effects could delay or stop the product's development.

Pfizer (PFE) and Amgen (AMGN) are also working on PCSK9 inhibitors.